deucravacitinib
bms
['deucra']
#eular2023 #pos0112 consistent with clinical response, post-hoc analyses of phase 2 rct of deucravacitinib (tyk2-i) showed this therapy suppressed both ifn and b cell pathways - a broader mode of action in reducing #sle pathophysiology. look forward to phase 3 results 
Rheumatologist. Interested in B-cells, Lupus, Sjogren, Pre-Connective Tissue Disease, Tennis, Running & Travelling 🌏